AR023261A1 - Empleo de arilalcanoilpiridazinas - Google Patents
Empleo de arilalcanoilpiridazinasInfo
- Publication number
- AR023261A1 AR023261A1 ARP000101547A ARP000101547A AR023261A1 AR 023261 A1 AR023261 A1 AR 023261A1 AR P000101547 A ARP000101547 A AR P000101547A AR P000101547 A ARP000101547 A AR P000101547A AR 023261 A1 AR023261 A1 AR 023261A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- independently represent
- atoms
- substituted
- represent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El empleo de las arilalcanoilpiridazinas de formula (1), en donde B representa A, OA, NH2, NHA, NAAo un heterociclo aromático con 1 a 4 átomos de N,O y/o S, el cual puede no estar sustituido o estar mono, di o trisustituido con Hal, A y/o OA; Q estáausente o representa alquileno C1-6; R1, R2 representanindependientemente -OH, OR5, -S-R5, -SO-R5, -SO2-R5, Hal, -NO2, -NH2, -NHR5 o -NR5R6; R1 y R2 juntos, también representan -O-CH2-O-; R5 y R6 representanindependientemente A, cicloalquilo C3-7,me tilencicloalquilo C4-8 o alquenilo C2-8; A, A representan independientemente alquilo C1-10, que puede estarsustituido con 1 a 5 átomos de F y/o Cl, y Hal representa F, Cl, Br o I; y/o de sus sales aceptables desde el punto de vista fisiologico,para prepararun medicamento destinado al tratamiento de la osteoporosis, los tumores, la aterosclerosis, la artritis reumatoidea, la esclerosis multiple, ladiabetes mellitus, la colitis ulcerativa y el SIDA. Estos compuestos inhiben selectivamentela fosf odiesterasa IV.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19915364A DE19915364A1 (de) | 1999-04-06 | 1999-04-06 | Verwendung von Arylalkanoylpyridazinen |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023261A1 true AR023261A1 (es) | 2002-09-04 |
Family
ID=7903583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000101547A AR023261A1 (es) | 1999-04-06 | 2000-04-05 | Empleo de arilalcanoilpiridazinas |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1143944A3 (es) |
JP (1) | JP2002541095A (es) |
KR (1) | KR20020000550A (es) |
CN (1) | CN1355702A (es) |
AR (1) | AR023261A1 (es) |
AU (1) | AU3811600A (es) |
BR (1) | BR0009549A (es) |
CA (1) | CA2367051A1 (es) |
CZ (1) | CZ20013598A3 (es) |
DE (1) | DE19915364A1 (es) |
HU (1) | HUP0200311A3 (es) |
ID (1) | ID30381A (es) |
MX (1) | MXPA01010034A (es) |
NO (1) | NO20014845L (es) |
PL (1) | PL350963A1 (es) |
RU (1) | RU2001129703A (es) |
WO (1) | WO2000059484A2 (es) |
ZA (1) | ZA200109120B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040087335A (ko) | 2002-03-01 | 2004-10-13 | 야마노우치세이야쿠 가부시키가이샤 | 질소 함유 복소환 화합물 |
DE10224888A1 (de) * | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
DE10225574A1 (de) * | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
WO2005002590A1 (ja) * | 2003-07-01 | 2005-01-13 | Astellas Pharma Inc. | 骨量増加誘導剤 |
AR067354A1 (es) * | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19632549A1 (de) * | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
DE19826841A1 (de) * | 1998-06-16 | 1999-12-23 | Merck Patent Gmbh | Arylalkanoylpyridazine |
DE19850701A1 (de) * | 1998-11-04 | 2000-05-11 | Merck Patent Gmbh | Benzoylpyridazine |
DE19915365A1 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Tetrahydropyridazin-Derivate |
-
1999
- 1999-04-06 DE DE19915364A patent/DE19915364A1/de not_active Withdrawn
-
2000
- 2000-03-15 PL PL00350963A patent/PL350963A1/xx unknown
- 2000-03-15 RU RU2001129703/15A patent/RU2001129703A/ru unknown
- 2000-03-15 AU AU38116/00A patent/AU3811600A/en not_active Abandoned
- 2000-03-15 CA CA002367051A patent/CA2367051A1/en not_active Abandoned
- 2000-03-15 EP EP00916949A patent/EP1143944A3/de not_active Withdrawn
- 2000-03-15 CN CN00805648A patent/CN1355702A/zh active Pending
- 2000-03-15 BR BR0009549-4A patent/BR0009549A/pt active Pending
- 2000-03-15 JP JP2000609048A patent/JP2002541095A/ja active Pending
- 2000-03-15 WO PCT/EP2000/002280 patent/WO2000059484A2/de not_active Application Discontinuation
- 2000-03-15 CZ CZ20013598A patent/CZ20013598A3/cs unknown
- 2000-03-15 KR KR1020017011993A patent/KR20020000550A/ko not_active Application Discontinuation
- 2000-03-15 MX MXPA01010034A patent/MXPA01010034A/es not_active Application Discontinuation
- 2000-03-15 HU HU0200311A patent/HUP0200311A3/hu unknown
- 2000-03-15 ID IDW00200102346A patent/ID30381A/id unknown
- 2000-04-05 AR ARP000101547A patent/AR023261A1/es unknown
-
2001
- 2001-10-05 NO NO20014845A patent/NO20014845L/no not_active Application Discontinuation
- 2001-11-05 ZA ZA200109120A patent/ZA200109120B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
NO20014845D0 (no) | 2001-10-05 |
DE19915364A1 (de) | 2000-10-12 |
CA2367051A1 (en) | 2000-10-12 |
ID30381A (id) | 2001-11-29 |
HUP0200311A2 (hu) | 2002-11-28 |
WO2000059484A2 (de) | 2000-10-12 |
CN1355702A (zh) | 2002-06-26 |
ZA200109120B (en) | 2003-11-13 |
EP1143944A2 (de) | 2001-10-17 |
MXPA01010034A (es) | 2002-04-24 |
JP2002541095A (ja) | 2002-12-03 |
RU2001129703A (ru) | 2004-02-20 |
HUP0200311A3 (en) | 2002-12-28 |
AU3811600A (en) | 2000-10-23 |
CZ20013598A3 (cs) | 2002-01-16 |
BR0009549A (pt) | 2002-03-26 |
EP1143944A3 (de) | 2002-09-11 |
NO20014845L (no) | 2001-10-05 |
PL350963A1 (en) | 2003-02-24 |
KR20020000550A (ko) | 2002-01-05 |
WO2000059484A3 (de) | 2001-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2022019I1 (no) | Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC | |
UY26727A1 (es) | Derivados de tropano útiles en terapia | |
AR038136A1 (es) | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento | |
ES2485867T3 (es) | Compuestos opioides de carboxamido | |
AR015419A1 (es) | Compuestos derivados de acidos ariloxialrilsulfonilamino hidroxamicos, composiciones y uso de dichos compuestos en la manufactura de medicamentos. | |
DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
PE20050130A1 (es) | Compuestos organicos | |
CO5700776A2 (es) | Compuestos utiles para el tratamiento de enfermedades | |
AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
CY1110355T1 (el) | Ενεργοποιητης του ενεργοποιουμενου απο πολλαπλασιαστη υπεροξυσωματων υποδοχεα δ | |
CO5540309A2 (es) | Derivados de 4-(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor, la ansiedad o desordenes gastrointestinales | |
FI940105A0 (fi) | Menetelmä sertraliinivälituotteiden valmistamiseksi | |
ES2184280T3 (es) | Compuestos de indol como inhibidores de cox-2'. | |
UY29070A1 (es) | Enantiómeros de heterocíclicos fusionados y sus usos | |
CO4700469A1 (es) | 3-[4-(4(4-cianofenil)-1-piperazinanil)butil]-5]ciannoindol y su proceso de obtencion . | |
AR023261A1 (es) | Empleo de arilalcanoilpiridazinas | |
AR021068A1 (es) | Benzoilpiridazinas y procedimientos para elaborarlas; preparados farmaceuticos que las contienen y procedimiento para elaborarlos, y utilizacion de dichasbenzoilpiridazinas | |
FI851996L (fi) | Nya substituerade bis-(4-aminofenyl) -sulfoner, deras framstaellning och deras anvaendning saosom laekemedel. | |
AR053989A1 (es) | Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas y procesos de obtencion. | |
AR019867A1 (es) | Uso de un derivado de pirrolidina para la fabricacion de un repelente contra insectos, acaros y garrapatas, dicho compuesto, una composicion que locomprende, un proceso para la preparacion de dicha composicion, y un proceso para repeler insectos de lugares y materiales | |
PE20040533A1 (es) | Esteres en posicion 20 de las camptotecinas | |
DK0500409T3 (da) | Derivater af 4-pyrimidinoler, deres fremstilling og anvendelse i therapien | |
AR045459A1 (es) | Tiofenos sustituidos y usos de los mismos | |
CO4750816A1 (es) | Derivados de bencenosulfonamida, su preparacion y su aplicacion en terapeutica | |
MX9101948A (es) | Composicion farmaceutica que contiene derivados de tiazoloisoindolinona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |